Related Experiment Videos
[Remission induction after pentoxifylline treatment in a patient with rheumatoid arthritis]
1Institute of Medical Science, Saint Marianna University School of Medicine, Kawasaki-city.
Abstract:
Pentoxifylline (POF) has been shown to have anti-inflammatory and immunomodulatory effects. including suppression of TNF-alpha production by activated macrophages, Th-1 response of T cells, and fibroblasts' proliferation and metalloproteinase production. Pentoxifylline was also reported to possess therapeutic properties in 50% of severe refractory RA in an open study. We experienced a 64 year-old man with seronegative RA, stage 2, class 3. He showed 23 swollen joints, 32 painful joints, ADL score 37/40, and ESR 135 mm/h. All these parameters were dramatically improved 3 weeks after administration of POF 300 mg/d and prednisolone 5 mg/d. Discontinuation of POF resulted in rapid exacerbation of RA. POF was restarted and the patient showed complete recovery from arthritis with normalization of ESR within 3 months and was maintained a complete remission for another 1 year. This case further supports a potential antirheumatic effect of POF on some patients with RA.
Insights
Pentoxifylline (POF) demonstrates significant anti-inflammatory effects, showing promise in treating rheumatoid arthritis (RA). This case study highlights POF
Area of Science:
- Immunology
- Pharmacology
Background:
- Pentoxifylline (POF) exhibits anti-inflammatory and immunomodulatory properties, including suppression of TNF-alpha, Th-1 response, and fibroblast activity.
- Previous studies suggest POF may have therapeutic benefits in refractory rheumatoid arthritis (RA).
Observation:
- A 64-year-old male with seronegative RA presented with severe symptoms: 23 swollen joints, 32 painful joints, low ADL score (37/40), and elevated ESR (135 mm/h).
Findings:
- Administration of POF (300 mg/d) with prednisolone (5 mg/d) led to dramatic improvement in all RA parameters within 3 weeks.
- Discontinuation of POF caused rapid RA exacerbation, while re-initiation resulted in complete remission, normalized ESR within 3 months, and sustained remission for 1 year.
Implications:
- This case supports the potential antirheumatic efficacy of Pentoxifylline in specific RA patient populations.
- Further research into POF's role in RA management is warranted.